How Should We Treat Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer?

被引：1

作者：

Takigawa, Nagio ^{[1
]}

机构：

[1] Kawasaki Med Sch, Dept Gen Internal Med 4, Kita Ku, 2-6-1 Nakasange, Okayama 7008505, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期

关键词：

OPEN-LABEL; ACQUIRED-RESISTANCE; CRIZOTINIB; CHEMOTHERAPY; IDENTIFICATION; INHIBITION; MUTATIONS; CERITINIB;

D O I：

10.1016/j.jtho.2018.07.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1438 / 1440

页数：3

共 22 条

[1] Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials [J].

Camidge, D. Ross ;

Kim, Dong-Wan ;

Tiseo, Marcello ;

Langer, Corey J. ;

Ahn, Myung-Ju ;

Shaw, Alice T. ;

Huber, Rudolf M. ;

Hochmair, Maximilian J. ;

Lee, Dae Ho ;

Bazhenova, Lyudmila A. ;

Gold, Kathryn A. ;

Ou, Sai-Hong Ignatius ;

West, Howard L. ;

Reichmann, William ;

Haney, Jeff ;

Clackson, Tim ;

Kerstein, David ;

Gettinger, Scott N. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (26) :2693-+

[2] Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2 [J].

Crino, Lucio ;

Ahn, Myung-Ju ;

De Marinis, Filippo ;

Groen, Harry J. M. ;

Wakelee, Heather ;

Hida, Toyoaki ;

Mok, Tony ;

Spigel, David ;

Felip, Enriqueta ;

Nishio, Makoto ;

Scagliotti, Giorgio ;

Branle, Fabrice ;

Emeremni, Chetachi ;

Quadrigli, Massimiliano ;

Zhang, Jie ;

Shaw, Alice T. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (24) :2866-+

[3] Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer [J].

Dagogo-Jack, Ibiayi ;

Azzolli, Christopher G. ;

Fintelmann, Florian ;

Mino-Kenudson, Mad ;

Farago, Anna F. ;

Gainor, Justin F. ;

Jiang, Ginger ;

Piotrowska, Zofia ;

Heist, Rebecca S. ;

Lennes, Inga T. ;

Temel, Jennifer S. ;

Mooradian, Meghan J. ;

Lin, Jessica J. ;

Digumarthy, Subba R. ;

Batten, Julie M. ;

Robinson, Hayley ;

Nose, Vania ;

Rivera, Miguel ;

Nardi, Valentina ;

Dias-Santagata, Dora ;

Le, Long P. ;

Sequist, Lecia, V ;

Pitman, Martha ;

Shepard, Jo-Anne O. ;

Shaw, Alice T. ;

Iafrate, A. John ;

Lennerz, Jochen K. .

JCO PRECISION ONCOLOGY, 2018, 2 :1-13

[4] SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors [J].

Dardaei, Leila ;

Wang, Hui Qin ;

Singh, Manrose ;

Fordjour, Paul ;

Shaw, Katherine X. ;

Yoda, Satoshi ;

Kerr, Grainne ;

Yu, Kristine ;

Liang, Jinsheng ;

Cao, Yichen ;

Chen, Yan ;

Lawrence, Michael S. ;

Langenbucher, Adam ;

Gainor, Justin F. ;

Friboulet, Luc ;

Dagogo-Jack, Ibiayi ;

Myers, David T. ;

Labrot, Emma ;

Ruddy, David ;

Parks, Melissa ;

Lee, Dana ;

DiCecca, Richard H. ;

Moody, Susan ;

Hao, Huaixiang ;

Mohseni, Morvarid ;

LaMarche, Matthew ;

Williams, Juliet ;

Hoffmaster, Keith ;

Caponigro, Giordano ;

Shaw, Alice T. ;

Hata, Aaron N. ;

Benes, Cyril H. ;

Li, Fang ;

Engelman, Jeffrey A. .

NATURE MEDICINE, 2018, 24 (04) :512-+

[5] Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer [J].

Gadgeel, Shirish M. ;

Shaw, Alice T. ;

Govindan, Ramaswamy ;

Gandhi, Leena ;

Socinski, Mark A. ;

Camidge, D. Ross ;

De Petris, Luigi ;

Kim, Dong-Wan ;

Chiappori, Alberto ;

Moro-Sibilot, Denis L. ;

Duruisseaux, Michael ;

Crino, Lucio ;

De Pas, Tommaso ;

Dansin, Eric ;

Tessmer, Antje ;

Yang, James Chih-Hsin ;

Han, Ji-Youn ;

Bordogna, Walter ;

Golding, Sophie ;

Zeaiter, Ali ;

Ou, Sai-Hong Ignatius .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) :4079-+

[6] Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial [J].

Gettinger, Scott N. ;

Bazhenova, Lyudmila A. ;

Langer, Corey J. ;

Salgia, Ravi ;

Gold, Kathryn A. ;

Rosell, Rafael ;

Shaw, Alice T. ;

Weiss, Glen J. ;

Tugnait, Meera ;

Narasimhan, Narayana I. ;

Dorer, David J. ;

Kerstein, David ;

Rivera, Victor M. ;

Clackson, Timothy ;

Haluska, Frank G. ;

Camidge, David Ross .

LANCET ONCOLOGY, 2016, 17 (12) :1683-1696

[7] The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) [J].

Golding, Brandon ;

Luu, Anita ;

Jones, Robert ;

Viloria-Petit, Alicia M. .

MOLECULAR CANCER, 2018, 17

[8] Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial [J].

Hida, Toyoaki ;

Nokihara, Hiroshi ;

Kondo, Masashi ;

Kim, Young Hak ;

Azuma, Koichi ;

Seto, Takashi ;

Takiguchi, Yuichi ;

Nishio, Makoto ;

Yoshioka, Hiroshige ;

Imamura, Fumio ;

Hotta, Katsuyuki ;

Watanabe, Satoshi ;

Goto, Koichi ;

Satouchi, Miyako ;

Kozuki, Toshiyuki ;

Shukuya, Takehito ;

Nakagawa, Kazuhiko ;

Mitsudomi, Tetsuya ;

Yamamoto, Nobuyuki ;

Asakawa, Takashi ;

Asabe, Ryoichi ;

Tanaka, Tomohiro ;

Tamura, Tomohide .

LANCET, 2017, 390 (10089) :29-39

[9] Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases [J].

Isozaki, Hideko ;

Ichihara, Eiki ;

Takigawa, Nagio ;

Ohashi, Kadoaki ;

Ochi, Nobuaki ;

Yasugi, Masayuki ;

Ninomiya, Takashi ;

Yamane, Hiromichi ;

Hotta, Katsuyuki ;

Sakai, Katsuya ;

Matsumoto, Kunio ;

Hosokawa, Shinobu ;

Bessho, Akihiro ;

Sendo, Toshiaki ;

Tanimoto, Mitsune ;

Kiura, Katsuyuki .

CANCER RESEARCH, 2016, 76 (06) :1506-1516

[10] Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer [J].

Isozaki, Hideko ;

Takigawa, Nagio ;

Kiura, Katsuyuki .

CANCERS, 2015, 7 (02) :763-783

← 1 2 3 →